Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral MG001

NCT07204171 is registered in ClinicalTrials.gov with National Institute on Drug Abuse (NIDA) as lead sponsor.

NCT NCT07204171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral MG001
Lead sponsor
National Institute on Drug Abuse (NIDA)
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
April 30, 2027
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety and tolerability in healthy subjects